Document resource
Background and Importance Aflibercept is a recombinant fusion protein that functions as a receptor binding vascular endothelial growth factor A and placental growth factor with greater affinity than their natural receptors. Recently marketed in 2024 at a dose of 8 mg/0.07 mL, it is indicated for the treatment of wet age-related macular degeneration (AMD) and diabetic macular oedema (DME) in adults.Aim and Objectives To evaluate the use of aflibercept 8 mg/0.07 mL in real-world clinical practice in patients with wet AMD and DME, both naive patients and previously treated.Material and Methods A unicentre, observational, descriptive, and retrospective study conducted from November 2024 to September 2025. Patients treated with aflibercept 8 mg/0.07 mL were included. Variables collected included demographics (age, sex), diagnosis, previous treatments, number and frequency of doses, reasons for discontinuation, and adverse events.After the three monthly loading doses, treatment intervals could be extended to 8 weeks (Q8), 12 weeks (Q12), or 16 weeks (Q16) if improvement in visual or anatomical outcomes was observed. Previously treated patients could follow a treat-and-extend regimen directly. Data were extracted from medical records.Results A total of 566 patients (56% male, 44% female) with a mean age of 71 ± 11 years and 775 treated eyes were included.Wet AMD: 42% (327 eyes). Naive eyes (24%; 84 eyes): 54% loading dose, 20% Q8, 15% Q12, 7% Q16, and 4% ineffective. Previously treated eyes (74%; 243 eyes): 26% loading dose, 49% Q8, 17% Q12, 3% Q16, and 3% ineffective.DME: 58% (443 eyes). Naive eyes (21%; 95 eyes): 56% loading dose, 18% Q8, 14% Q12, 8% Q16, and 3% ineffective. Previously treated eyes (79%; 348 eyes): 41% loading dose, 39% Q8, 15% Q12, 2% Q16, and 3% ineffective.Two patients reported adverse events of reduced visual acuity, ocular pain, and blurred vision.Conclusion and Relevance Aflibercept 8 mg/0.07 mL showed effective outcomes and good tolerance in both naive and previously treated eyes with wet AMD and DME. In our real-world practice, most patients remain on Q8 intervals, with few yet reaching Q16–Q20 extensions as described in the product label. Continued follow-up is needed to assess longer-term interval outcomes.Conflict of Interest No conflict of interest